Literature DB >> 8646697

The National Cancer Data Base report on lung cancer.

W A Fry1, H R Menck, D P Winchester.   

Abstract

BACKGROUND: Previous Commission on Cancer data from the National Cancer Data Base (NCDB) have examined time trends in stage of disease, treatment patterns, and survival for selected cancers. The most current (1992) data for lung cancer are described here.
METHODS: Four Calls for Data have yielded a total of 560,455 lung cancer cases diagnosed in 1986-1987 and 599,597 cancer cases diagnosed in 1992, from hospital cancer registries across the United States.
RESULTS: A total of 91,115 lung cancer cases diagnosed in 1986-1987 and 92,182 diagnosed in 1992 were reported from cancer registries across the United States. Lung cancer occurs mainly in patients between the ages of 50 and 80 years. There was an increasing relative frequency of adenocarcinoma, and of lung cancer in women, and a noteworthy poor prognosis among African Americans. Lung cancer patients were reported from all types and sizes of hospitals in America, from smaller community hospitals to major teaching centers. Treatment by surgical resection occurred more frequently in the major cancer centers. The overall prognosis for lung cancer remains extremely poor.
CONCLUSIONS: For a selective category of patients (Stage I), cancer-directed surgery offers reasonable cure rates, but these data underline the need for earlier diagnosis and improved treatment modalities in the overall management of lung cancer patients.

Entities:  

Mesh:

Year:  1996        PMID: 8646697     DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Thoracic surgery in a crisis.

Authors:  Martyn R Partridge
Journal:  BMJ       Date:  2002-02-16

Review 2.  The lung cancer paradox: time for action.

Authors:  R C Rintoul; T Sethi
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 3.  After Detection: The Improved Accuracy of Lung Cancer Assessment Using Radiologic Computer-aided Diagnosis.

Authors:  Guy J Amir; Harold P Lehmann
Journal:  Acad Radiol       Date:  2015-11-23       Impact factor: 3.173

4.  Hospital volume and surgical outcomes of lung cancer in Japan.

Authors:  Hiroaki Osada; Etsuko Yamakoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-09

5.  Evidence based radiation oncology with existing technology.

Authors:  Nicolas Isa
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-14

6.  Pulmonary nodules 10 mm or less in diameter with ground-glass opacity component detected by high-resolution computed tomography have a high possibility of malignancy.

Authors:  Hyung-Eun Yoon; Kenjiro Fukuhara; Toshiya Michiura; Minoru Takada; Masami Imakita; Kentaro Nonaka; Kazuhiro Iwase
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-01

Review 7.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

8.  Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro.

Authors:  Javorina Milosević; Selma Kanazir; Ljubica Medić-Mijacević; Vjera Pejanović; Zdenka Stokić; Gordana Konjević; Ljubisa Rakić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

9.  Baseline FACT-G score is a predictor of survival for advanced lung cancer.

Authors:  M Dharma-Wardene; H J Au; J Hanson; D Dupere; J Hewitt; D Feeny
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

10.  Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).

Authors:  S Hosoe; K Komuta; K Shibata; H Harada; Y Iwamoto; Y Ohsaki; T Morioka; H Origasa; M Fukushima; K Furuse; M Kawahara
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.